Navigation Links
PhRMA Applauds House Committee on Foreign Affairs Commitment to Continuing Efforts to Fight AIDS, Tuberculosis, and Malaria Epidemics
Date:2/29/2008

WASHINGTON, Feb. 28 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today released the following statement on the passage of the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis and Malaria Reauthorization Act (H.R. 5501) by the United States House Committee on Foreign Affairs:

"America's pharmaceutical research companies commend the House Committee on Foreign Affairs for passing the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis and Malaria Reauthorization Act (H.R. 5501). This admirable bipartisan bill will allow for the continuation of the unprecedented programs and partnerships implemented by the President's Emergency Plan for AIDS Relief (PEPFAR), the President's Malaria Initiative (PMI) and other global health programs.

"We are committed to fighting the global HIV, TB and malaria epidemics and we look forward to continuing to work with the partnerships created by PEPFAR and PMI to find new, innovative solutions to fight these diseases.

"The reauthorization of these initiatives is a groundbreaking step in worldwide efforts. Already, PEPFAR has provided care or treatment for over 6.6 million people infected or affected by HIV/AIDS, including 2.7 million orphans and vulnerable children.

"This bill provides much needed resources to halt the 6,000 new HIV infections that occur every day and the approximately 6 million deaths from HIV, TB and malaria that occur every year, primarily in Africa.

"This bill and the promise it holds for curbing the AIDS, TB and malaria epidemics is a great tribute to the inspirational leadership of the late former chairmen of the Committee, Rep. Tom Lantos and Rep. Henry J. Hyde."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry-wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America(PhRMA)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PhRMA Celebrates 20th Anniversary of Discoverers Award
2. PhRMA Statement on Enactment of FDA Legislation
3. AGA Institute applauds delay of Aetna sedation restrictions
4. TFAH Applauds Release of CDCs State-Specific Public Health Emergency Preparedness Report
5. OrthoSynetics(TM) Applauds SEC Suit Against Former Company Management
6. Psoriasis Cure Now Applauds Record Government Psoriasis Research Funding
7. PCMA Applauds Secretary Leavitts Support for Requiring E-Prescribing in Medicare
8. Training Magazine Applauds Aflacs Employee Learning Programs
9. MedeFile Applauds U.S. Presidential Hopefuls for Advocating Widespread Adoption of Electronic Medical Records
10. Blunt Applauds Passage of Republican-Crafted SCHIP Extension
11. IOF applauds NOS on NICE Guidance appeal success and urges continued efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... modern procedure that achieves results in a fraction of the time as traditional ... NV, with Significance Dental Specialists, now offers this revolutionary treatment with or without ...
(Date:4/25/2017)... ... ... Back Pain Centers of America (BPC), which connects people searching ... area, announces the launch of a new and proprietary customer relationship management (CRM) system ... physicians to help them with back or neck pain and helps to match them ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, ... to its patient care management module. Using this new feature, sleep physicians can ... been initiated on continuous positive airway pressure (CPAP), oral, or other forms of ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: